NIR Fluorescence Imaging of Lymphatic Transport Using ICG

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Indocyanine Green

A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.

DEVICE

MultiSpectral Imaging System

Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.

Trial Locations (1)

14642

University of Rochester, Rochester

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

University of Rochester

OTHER

NCT02680067 - NIR Fluorescence Imaging of Lymphatic Transport Using ICG | Biotech Hunter | Biotech Hunter